Neumora Therapeutics is trading 7.01% down at $1.06, continuing a multiday decline from $1.33 on September 1, 2026, with no clear company-specific catalyst identified for September 11, 2026.
- The broader market is rising, so current evidence does not support attributing the decline to overall market weakness.
- Recent coverage primarily references older pipeline and clinical developments rather than a new catalyst.